Alpha Pro Tech: Record N95 mask orders and stock plunge

Alpha Pro Tech: From $22 million in mask orders to stock market punishment

How can a company quadruple its profit in a single quarter yet trade far below its pandemic-era purchase prices? Alpha Pro Tech (APT), a maker of disposable protective gear, masks, and construction products, is a textbook case. On March 11, 2020, it announced reserved orders for its N-95 respirator totaling $22.6 million since January 27, a 60% increase over $14.1 million recorded by February 27. The charts, the company said, were very bullish.

From $22.6 million to $36.7 million in orders over three months

The company expected to fulfill about $4 million of those orders in the first quarter of 2020 and deliver the remaining $18.6 million by early third quarter, with accelerated N-95 mask production scheduled to complete by early May. It was not an illusion: on April 7, the reserved figure had already climbed to $36.7 million since January 27.

Political tailwinds arrived in parallel. Senator Lindsey Graham insisted that the United States buy protective equipment from domestic companies to reduce dependence on China; Walmart made masks mandatory in its stores; and the new Biden administration linked itself to mandatory mask plans and mass vaccination. Each announcement served as an excuse for another jump in value.

A first quarter with sales 47.5% higher

The numbers trinc. The quarter ending March 31, 2020, showed sales growth of 47.5% and diluted earnings per share of $0.39, more than 300% higher than the previous year. Those looking only at the balance sheet saw a machine: those trinc the value held an invested capital return of 94%, a price-to-earnings ratio (PER) reading as low as 7, an EV/EBITDA of 7, and near-zero debt. The line-by-line breakdown of that income statement explains why many decided to hold positions despite the falling price.

Why a stock with a PER of 3 falls

Because the market began to discount that the extraordinary business had an expiration date. Added to this was a technical factor dominating the conversation: the high presence of short positions. Some argue that this bearish pressure is coordinated manipulation and that the price is intervened; no public data confirms this, and the simplest explanation—the end of the emergency order cycle—suffices to justify the punishment. What the thread records is the result: a session with a 20% drop, entries moving from $20 to $14, then to $7, and finally to $6, with a value, according to forum calculations, trading at a capitalization lower than its own revenue figure.

Less revenue, less profit, and less debt

Results with data as of June 30, 2021, confirmed the cooling. Revenue fell from $43.5 million to $40.9 million; EBITDA from $21.1 million to $15 million; profit from $12 million to $7 million. Debt, however, continued to shrink: from $9 million to $5 million. The company maintained share repurchase and amortization of its own stock. With these figures on the table, the additional 20% drop on the presentation day seemed debatable for those expecting another reaction from already heavily punished prices.

Mandatory masks again: the rebound argument

With the return of mask mandates and a rise in cases, part of the analysis holds that winter should return demand, with the N-95 established in hospitals and governments accumulating reserves for future pandemics. The opposing view sees it as an illusion: Chinese products flooded the market, the barrier to entry for the business is minimal, and no company is guaranteed the jackpot. Both positions have been defended with equal conviction, at the same price, with neither yet winning the debate.

In the end, it turns out you can manufacture one of the most demanded products in the world, make money from it, and still end up explaining at home why the chart is in the red. Nobody said the stock market was a ministry of health.